What's Happening?
Pfizer's investigational antibody-drug conjugate, sigvotatug vedotin, did not achieve statistically significant overall survival benefits in a Phase 3 study for non-small cell lung cancer (NSCLC). The study, known as SigVie-002, focused on patients with
unresectable or metastatic non-squamous NSCLC who had undergone one or more prior treatments. Despite the overall failure, Pfizer noted promising signals of efficacy in a subgroup of patients who had only one prior line of treatment. Analysts from Leerink Partners and Guggenheim Securities expressed disappointment with the results, which were anticipated due to the challenges other agents have faced in surpassing the chemotherapy drug docetaxel's survival improvements.
Why It's Important?
The failure of sigvotatug vedotin to improve overall survival in this study is a setback for Pfizer, which acquired the drug through its $43 billion purchase of Seagen. The results highlight the ongoing challenges in developing effective treatments for NSCLC, a leading cause of cancer-related deaths. Despite the setback, Pfizer plans to continue testing the drug in combination with other therapies, such as Merck's Keytruda, in hopes of finding a more effective treatment regimen. The outcome of these studies could impact Pfizer's strategy in the oncology market and its goal to deliver multiple blockbuster cancer therapies by 2030.
What's Next?
Pfizer intends to continue exploring the potential of sigvotatug vedotin in combination with other treatments, including Keytruda, in ongoing trials. The company is also investigating the drug's use in earlier treatment settings where immune competence is better preserved. Additionally, Pfizer is developing new generations of antibody-drug conjugates targeting the same protein, integrin beta-6, with different cancer cell-killing payloads. These efforts aim to enhance the drug's efficacy and expand its application across various cancer types.
